Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $62000.0.

  • Lyell Immunopharma's Capital Expenditures rose 508.47% to $62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $520000.0, marking a year-over-year increase of 1685.39%. This contributed to the annual value of $464000.0 for FY2024, which is 8272.52% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Capital Expenditures stood at $62000.0, which was up 508.47% from $168000.0 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Capital Expenditures peaked at $24.4 million during Q2 2021, and registered a low of $25000.0 during Q4 2023.
  • In the last 5 years, Lyell Immunopharma's Capital Expenditures had a median value of $933000.0 in 2023 and averaged $4.9 million.
  • Per our database at Business Quant, Lyell Immunopharma's Capital Expenditures tumbled by 9945.44% in 2023 and then surged by 7600.0% in 2024.
  • Lyell Immunopharma's Capital Expenditures (Quarter) stood at $10.3 million in 2021, then tumbled by 55.38% to $4.6 million in 2022, then plummeted by 99.45% to $25000.0 in 2023, then surged by 76.0% to $44000.0 in 2024, then surged by 40.91% to $62000.0 in 2025.
  • Its Capital Expenditures stands at $62000.0 for Q3 2025, versus $168000.0 for Q2 2025 and $246000.0 for Q1 2025.